| چکیده انگلیسی مقاله |
Background: Limited data exists regarding the status of long-term cardiovascular outcomes of hospitalized COVID-19 patients. We also aimed to examine the efficacy of early statin use after SARS-CoV2 pneumonia and impact of prior CVD on incidence of cardiovascular events.
Methods: A prospective cohort study was performed among hospitalized COVID-19 patients. Primary endpoint was major adverse cardiovascular events (MACE) as a composite of cardiovascular mortality, stroke, heart failure, VTE, revascularization, and non-fatal MI. Secondary endpoints included MACE components, all-cause mortality, readmission for COVID-19, and impaired functional class.
Results: Mean age of the 858 participants was 55.52±13.97 years and median follow up time was 13 months (11.5-15). Male subjects comprised 63.9 % of the patients .Overall, MACE occurred in 84 subjects (9.8%) and 98 patients (11.4%) received ventilation. Multivariate Cox-regression explored the association of statin use and outcomes. Hazard ratios (HR) were as following: MACE (0.831 (0.529-0.981) P=0.044), All-cause mortality ((1.098 (0.935-1.294) P=0.255), Stroke (0.118 (0.029-0.48) P=0.003) , Revascularization (0.103 (0.029-0.367) P< 0.0001), poor functional capacity (0.827(0.673-1.018) P=0.073), Non-fatal MI (0.599 (0.257- 1.394) P=0.234,), VTE (0.376 (0.119- 1.190) P=0.096), and decompensated Heart failure (0.137 (0.040- 0.472) P=0.002). Prior CVD predicted MACE (2.953 (1.393-6.271) P=0.005), all-cause death (1.170 (0.960-1.412) P=0.102) and VTE (2.770 (0.957- 8.955) P=0.051).
Conclusion: Previous CVD is a robust predictor of long-term MACE and VTE. Early statin use might decrease incidences of MACE, ischemic stroke, revascularization, and readmission for heart failure. |
| نویسندگان مقاله |
| Arezoo Khosravi
Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
| Saeed Ghodsi
1-Atherosclerosis Research Center, Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. 2- Department of Cardiology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran. 3- Cardiovascular Diseases Research Institute, Tehran Heart Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
| Mohammadreza Memarjafari
Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
| Alireza Nematollahi
Cardiovascular Diseases Research Institute, Tehran Heart Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
| Reza Sharbafan
Cardiovascular Diseases Research Institute, Tehran Heart Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
| Seyed-Ali Sadre-Bafghi
Afshar Hospital, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
| Seyed-Vahid Moosavi
Atherosclerosis Research Center, Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
| Mansour Abdollahzadeh
Atherosclerosis Research Center, Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
| Arash Jalali
Cardiovascular Diseases Research Institute, Tehran Heart Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
| Maryam Moshkani Farahani
Atherosclerosis Research Center, Clinical Sciences Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
|